NDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAXON is a topical ophthalmic suspension containing levobetaxolol hydrochloride, a beta-1 selective adrenergic antagonist used to reduce intraocular pressure in glaucoma and ocular hypertension. It is administered as eye drops and represents a selective beta-blocker class for ocular use.
LOE Approaching
As an established product nearing loss of exclusivity with moderate competitive pressure (30%), this represents a mature-stage brand requiring defensive positioning and cost-optimization strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
78 enrolled
GlaucomaOcular Hypertension
Career Relevance
Working on BETAXON offers experience in mature product management, competitive defense, and ophthalmology-focused commercial execution within Alcon's established portfolio. Career progression will emphasize margin protection, market access, and transition strategies rather than launch growth.
Worked on BETAXON at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.